Physician profile
Shannon L Welner
NPI 1497966980
$175,891.63
in general payments reported to CMS, 2019-2025
32 companies · $73K in 2025
The $73K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $9,467 · 2022: $22K · 2023: $31K · 2024: $41K · 2025: $73K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $95K · Honoraria: $20K · Food and Beverage: $19K · Travel and Lodging: $6,938 · Consulting Fee: $2,313 · Education: $603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $95,417.50 |
| Honoraria | $19,785.08 |
| Food and Beverage | $19,452.47 |
| Travel and Lodging | $6,938.20 |
| Consulting Fee | $2,312.50 |
| Education | $602.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $90,884.24 | 2021-2025 | Aklief, Twyneo, Nemluvio |
| Incyte Corporation | $23,695.31 | 2021-2025 | Opzelura, Opzelura |
| Organon LLC | $23,629.49 | 2024-2025 | Vtama |
| Abbvie INC. | $15,120.96 | 2021-2025 | |
| Botanix Sb INC | $4,329.98 | 2025 | Sofdra |
| Janssen Biotech, INC. | $2,886.44 | 2021-2025 | Tremfya, Simponi, Stelara |
| Genzyme Corporation | $2,420.30 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $2,029.51 | 2021-2025 | Winlevi, Blu-U, Odomzo |
| Arcutis Biotherapeutics, INC. | $1,712.39 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $1,236.94 | 2021-2025 | Adbry, Anzupgo |
| Pfizer INC. | $1,096.55 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $952.91 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $851.41 | 2022-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $806.15 | 2021-2025 | |
| Journey Medical Corporation | $735.97 | 2021-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $663.37 | 2021-2024 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $584.68 | 2021-2025 | Dupixent, Libtayo |
| Amgen INC. | $448.29 | 2021-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $405.87 | 2021-2024 | Cabtreo, Jublia, Arazlo |
| Almirall LLC | $354.61 | 2021-2025 | Klisyri, Seysara |
| Vyne Pharmaceuticals INC. | $294.60 | 2021 | |
| Ucb, INC. | $235.62 | 2021-2025 | Bimzelx, Cimzia |
| Mayne Pharma Commercial LLC | $125.61 | 2021-2025 | |
| Epi Health, LLC | $108.77 | 2021-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $95.39 | 2021-2025 | Valchlor |
| Fidia Pharma USA INC. | $38.72 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.46 | 2022 | |
| Blueprint Medicines Corporation | $31.68 | 2023-2024 | Ayvakit |
| Nabriva Therapeutics, Plc | $27.72 | 2022 | |
| Sanofi-Aventis U.S. LLC | $18.83 | 2024 | |
| Sanofi US Services INC. | $16.90 | 2024 | |
| Strata Skin Sciences, INC. | $13.96 | 2025 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Welner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.